CompletedNCT01911429
Lurasidone Safety and Efficacy in Children and Adolescents With Schizophrenia
About this title
Read the official source — NCT01911429Researchers compared Lurasidone 40 mg, Lurasidone 80 mg and placebo to find out how the approaches affected psychotic symptoms in young people with schizophrenia.
Medication studyAges 13–17Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Lurasidone 40 mg, Lurasidone 80 mg and placebo to find out how the approaches affected psychotic symptoms in young people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Dothan and 89 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 327
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, United Kingdom, ...
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT01911429
- Official title
Show the full official title
A 6-Week Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Dothan, United States · Anaheim, United States · Bakersfield, United States
85 more locations
- Culver City, United States
- Downey, United States
- Garden Grove, United States
- Irvine, United States
- Orange, United States
- Panorama City, United States
- Riverside, United States
- Hartford, United States
- Washington D.C., United States
- Bradenton, United States
- Gainesville, United States
- Orlando, United States
- Sanford, United States
- Atlanta, United States
- Smyrna, United States
- Naperville, United States
- Lake Charles, United States
- Baltimore, United States
- Bloomfield Hills, United States
- Neptune City, United States
- New York, United States
- Rochester, United States
- Staten Island, United States
- Cincinnati, United States
- Cleveland, United States
- Oklahoma City, United States
- Memphis, United States
- Austin, United States
- Dallas, United States
- El Campo, United States
- The Woodlands, United States
- Orem, United States
- Charlottesville, United States
- Brussels, Belgium
- Rousse, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Varna, Bulgaria
- Barranquilla, Colombia
- Bello, Colombia
- Bogotá, Colombia
- Nantes, France
- Nice, France
- Budapest, Hungary
- Gyula, Hungary
- Lembah Pantai, Malaysia
- Culiacán, Mexico
- Monterrey, Mexico
- Daveo City, Philippines
- Iloilo City, Philippines
- Mandaluyong, Philippines
- Quezon City, Philippines
- Torun, Poland
- Tyniec Mały, Poland
- Warsaw, Poland
- Caguas, Puerto Rico
- Ponce, Puerto Rico
- San Juan, Puerto Rico
- Bucharest, Romania
- Iași, Romania
- Timișoara, Romania
- Lipetsk, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Tomsk, Russia
- Velikiy Novgorod, Russia
- Yekaterinburg, Russia
- Incheon, South Korea
- Jeonju, South Korea
- Seoul, South Korea
- Torremolinos, Spain
- Barcelona, Spain
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kherson,Vil. Stepanivka, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Ternopil, Ukraine
- Vinnytsia, Ukraine
- Aberdeen, United Kingdom
- Birmingham, United Kingdom
- Edinburgh, United Kingdom
- Russia
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Lurasidone 40 mg, Lurasidone 80 mg and placebo to find out how the approaches affected psychotic symptoms in young people with schizophrenia.
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone 40 mg, Lurasidone 80 mg and Placebo 40 or 80 mg.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia